Eleanor Kennedy summarises a recent Cochrane review of pharmacotherapy for chronic cognitive impairment in traumatic brain injury, which finds insufficient evidence to support its use.
[read the full story...]Rivastigmine for Alzheimer’s: is a small cognitive ‘improvement’ worth the risk of feeling physically unwell?
Rosalyn Nelson presents the latest Cochrane systematic review of Rivastigmine for Alzheimer’s disease, which brings together the results of 7 industry sponsored or funded trials, and concludes that Rivastigmine may be of benefit to people with Alzheimer’s disease.
[read the full story...]